Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses.

Panagiotis A KonstantinopoulosSu-Chun ChengElizabeth K Lee Alexandre Andre Balieiro Anastacio da Costa Doga C Gulhan Andrea E Wahner Hendrickson Bose S Kochupurakkal David L KolinElise C KohnJoyce F Liu Richard T Penson Elizabeth H StoverJennifer CurtisHannah SawyerMadeline PolakDipanjan ChowdhuryAlan D' AndreaAnniina FärkkiläGeoffrey I Shapiro Ursula A Matulonis

Published in: JCO precision oncology (2024)

The results of this follow-up analysis continue to support the promise of combined gemcitabine/ATRi therapy in platinum resistant ovarian cancer, an active area of investigation with several ongoing clinical trials.

Keyphrases

phase ii study
open label
locally advanced
clinical trial
placebo controlled
phase ii
double blind
phase iii
rectal cancer
squamous cell carcinoma
radiation therapy
study protocol
randomized controlled trial
stem cells
big data
free survival
artificial intelligence
smoking cessation